The effect of hypoprolactinemia on cardiometabolic effects of rosuvastatin in men: A matched Cohort Pilot Study
An erratum to this article was published (Pituitary, 18 Aug 2026 ↗)
Authors' conclusion
These findings suggest that hypoprolactinemia may worsen cardiometabolic outcomes in men receiving rosuvastatin therapy.
Study context
- Population
- Men with indications for statin therapy, all receiving rosuvastatin for six monthsmatched cohort
- Participants
- 16 / 23 / 37
- Exposure
- Hypoprolactinemia vs normal prolactin levels in men receiving rosuvastatin
- Group 1n = 16
- Groups 2n = 23
- 3n = 37reference
- Outcome
- Cardiometabolic effects of rosuvastatin
- Follow-up
- Six months
Main finding
As reported in the abstract
- Rosuvastatin reduced total and LDL cholesterol in all groups, with a greater effect in groups 2 and 3
- Reductions in high-sensitivity C-reactive protein (hs-CRP), fibrinogen, uric acid, homocysteine and urinary albumin-to-creatinine ratio (UACR) only in groups with normal prolactin
- Group 1 had increases in HbA1c and HOMA-IR
- At study end, carotid intima-media thickness (CIMT) greater in group 1 than in groups 2 and 3; groups 2 and 3 comparable
- In hypoprolactinemia, rosuvastatin effects on lipids, hs-CRP, fibrinogen, uric acid, homocysteine, UACR, HbA1c, HOMA-IR and CIMT correlated with baseline and posttreatment prolactin
Observational data: associations, not effects.
Further findings
Baseline characteristics
- Men with hypoprolactinemia had higher hs-CRP, fibrinogen, homocysteine, UACR, HbA1c and HOMA-IR, and lower testosterone than those with normal prolactin
Original publication
The effect of hypoprolactinemia on cardiometabolic effects of rosuvastatin in men: A matched Cohort Pilot Study. Pituitary. Published 1 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →